PEPG
PepGen Inc.
$5.56
+$0.47(+9.23%)
70
Overall
60
Value
81
Tech
--
Quality
Market Cap
$149.24M
Volume
1.84M
52W Range
$0.88 - $6.85
Target Price
$10.00
Company Overview
| Mkt Cap | $149.24M | Price | $5.56 |
| Volume | 1.84M | Change | +9.23% |
| P/E Ratio | -1.7 | Open | $5.16 |
| Revenue | -- | Prev Close | $5.09 |
| Net Income | $-90.0M | 52W Range | $0.88 - $6.85 |
| Div Yield | N/A | Target | $10.00 |
| Overall | 70 | Value | 60 |
| Quality | -- | Technical | 81 |
No chart data available
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Latest News
PepGen Inc. (PEPG) Gets a Sell from Bank of America Securities
TipRanks Auto-Generated Intelligence Newsdesk•8 days ago
H.C. Wainwright Keeps Their Buy Rating on PepGen Inc. (PEPG)
TipRanks Auto-Generated Intelligence Newsdesk•10 days ago
PepGen Inc. Reprices Underwater Stock Options
TipRanks Auto-Generated Newsdesk•16 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PEPG | $5.56 | +9.2% | 1.84M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |